Phase III studies in prostatic cancer with leuprolide acetate.
作者信息
Seely J H
出版信息
J Androl. 1987 Jan-Feb;8(1):S23-6.
PMID:3104263
Abstract
摘要
相似文献
1
Phase III studies in prostatic cancer with leuprolide acetate.醋酸亮丙瑞林治疗前列腺癌的III期研究。
J Androl. 1987 Jan-Feb;8(1):S23-6.
2
Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced cancer of the prostate.
Br J Clin Pract Suppl. 1985 Mar;37:8-12, 20-4.
3
4
Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial.
Urology. 1986 Jan;27(1 Suppl):21-8.
5
Leuprolide for prostate cancer.
Med Lett Drugs Ther. 1985 Aug 16;27(694):71-2.
6
Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer.亮丙瑞林：一种用于前列腺癌姑息治疗的促性腺激素释放激素类似物。
Drug Intell Clin Pharm. 1986 Oct;20(10):746-51. doi: 10.1177/106002808602001001.
7
LHRH analogues in the treatment of prostatic cancer. Introduction.促性腺激素释放激素类似物在前列腺癌治疗中的应用。引言。
Br J Clin Pract Suppl. 1985 Mar;37:2-3, 14-5.
8
Hormonal therapy for prostate cancer.前列腺癌的激素治疗
N Engl J Med. 1984 Nov 15;311(20):1313-4. doi: 10.1056/NEJM198411153112010.
9
Preliminary clinical evaluation of leuprorelin acetate depot injection in France, in the management of prostatic cancer.
J Int Med Res. 1990;18 Suppl 1:69-73. doi: 10.1177/03000605900180S110.
10
Clinical experience of hormone therapy to bone metastatic prostate cancer.激素疗法治疗骨转移性前列腺癌的临床经验
Int J Urol. 2006 May;13(5):550-4. doi: 10.1111/j.1442-2042.2006.01345.x.
引用本文的文献
1
Intracrine androgen biosynthesis and drug resistance.内分泌雄激素生物合成与耐药性。
Cancer Drug Resist. 2020 Nov 3;3(4):912-929. doi: 10.20517/cdr.2020.60. eCollection 2020.
Zotero 插件